Kelly E Gridley

US Patent:

59729236, Oct 26, 1999

Filed:

Jan 16, 1998

Appl. No.:

9/007915

Inventors:

James W. Simpkins - Gainesville FL
Kelly E. Gridley - Gainesville FL
Pattie S. Green - Gainesville FL

Assignee:

University of Florida Research Foundation, Inc. - Gainesville FL

International Classification:

A61K 3156
A61K 3800
A61K 31355
A61K 3304

US Classification:

514182

Abstract:

The present invention concerns methods and compositions for enhancing the cytoprotective effects of polycyclic phenolic compounds through the synergistic interaction with anti-oxidants.

US Patent:

62076582, Mar 27, 2001

Filed:

Aug 4, 1998

Appl. No.:

9/128862

Inventors:

James W. Simpkins - Gainesville FL
Pattie S. Green - Gainesville FL
Kelly E. Gridley - Gainesville FL

Assignee:

University of Florida Research Foundation, Inc. - Gainesville FL

International Classification:

A61K31/56;31/35

US Classification:

514182

Abstract:

A method is provided for preserving tissues during removal, storage and implantation into a subject by enhancing cell viability in a population of graft cells during the transplantation procedure. The method includes selecting an effective dose of a polycylic phenolic compound in a physiologically acceptable formulation and exposing at least the population of graft cells to the formulation containing the compound within a time that is effectively proximate to the transplantation procedure so as to confer cytoprotection on the population of graft cells.

US Patent:

58246720, Oct 20, 1998

Filed:

Jan 10, 1997

Appl. No.:

8/782883

Inventors:

James W. Simpkins - Gainesville FL
Pattie S. Green - Gainesville FL
Kelly E. Gridley - Gainesville FL

Assignee:

University of Florida Research Foundation, Inc. - Gainesville FL

International Classification:

A61K 3156

US Classification:

514182

Abstract:

A method is provided for preserving tissues during removal storage and implantation by enhancing cell viability in a population of graft cells during the transplantation procedure The method includes selecting an effective dose of a cyclopentanophenanthrene compound having a terminal phenol A ring in a physiologically acceptable formulation and exposing at least one of: a donor at an effective dose prior to removal of the cells; the population of cells in an ex vivo storage medium;, and a recipient tissue at an effective time prior to association with the donor graft cells; so as to confer cytoprotection on the population of graft cells.